Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Child Neurology|September 8, 2025
An Occurrence of Mass Psychogenic Illness: LeRoy, New YorkJennifer McVige, Lanie Masset, Laszlo Mechtler, et al.
Orvosi Hetilap|February 4, 2010
[Measurement of indoor smoke pollution in public places in Hungary]Dávid László Tárnoki, Adám Domonkos Tárnoki, Andrew Hyland, et al.
Neurology|February 20, 2025
Real-world Evidence of Adding Atogepant to OnabotulinumtoxinA for Control of Chronic Migraine: A Retrospective Chart Review (P4-12.001)Andrew Blumenfeld, Laszlo Mechtler, Lisa Cook, et al.
Clinical Neuropharmacology|May 16, 2023
Medical Cannabis in the Treatment of Parkinson's DiseaseTraci S Aladeen, Anna G Mattle, Kory Zelen, et al.
Pain and Therapy|September 17, 2024
Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart ReviewAndrew M Blumenfeld, Laszlo Mechtler, Lisa Cook, et al.
Cancer|April 4, 2003
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant gliomaDavid N Korones, Michal Benita-Weiss, Thomas E Coyle, et al.
Cephalalgia : an International Journal of Headache|August 28, 2023
Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trialRichard B Lipton, Rashmi B Halker Singh, Laszlo Mechtler, et al.
Cephalalgia : an International Journal of Headache|January 9, 2023
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trialBrad C Klein, Rosa Miceli, Lawrence Severt, et al.
BMC Public Health|February 3, 2026
Economic burden of stroke attributable to excess body mass in Hungary: a population-attributable fraction analysisTamas Jarecsny, Csilla Arvane Egri, Roland Kosik, et al.
Neuro-Oncology|April 4, 2003
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant gliomaMichael D Prados, S Clifford Schold, Howard A Fine, et al.
Pageof 3